Lovisa Afzelius
Fondateur chez Elsa Science AB
Profil
Lovisa Afzelius is the founder of Elsa Science AB, where she holds the title of Chairman since 2017.
Dr. Afzelius is also the founder of Prologue Medicines, Inc. Dr. Afzelius's current job is the Founding Chief Executive Officer & Director at Alltrna.
Dr. Afzelius's former job was as the Chief Executive Officer at BioChromix Pharma AB.
Dr. Afzelius obtained a doctorate degree from the University of Uppsala.
Postes actifs de Lovisa Afzelius
| Sociétés | Poste | Début |
|---|---|---|
Elsa Science AB
 Elsa Science AB Information Technology ServicesTechnology Services Elsa Science AB provides mobile applications that helps in learning medication and living habits that affect arthritis rheumatism. The firm specializes in healthcare, life science, chronic diseases, research, health and prevention. The company was founded by Sofia Svanteson, Sebastian Evans, Pelle Almquist, Lars Alfredsson and Lovisa Afzelius and is headquartered in Stockholm, Sweden. | Fondateur | 01/01/2017 |
Alltrna
 Alltrna BiotechnologyHealth Technology Alltrna is a biotech company that uses AI/ML tools to learn the language of tRNA and develop programmable molecules with therapeutic potential. Alltrna was founded in 2018 by Flagship Pioneering and is based in Cambridge, MA. The company aims to correct diseases by advancing a single tRNA medicine to treat a wide range of diseases with the same underlying genetic mutation. The company's CEOs are Michelle C. Werner and Lovisa Afzelius. | Directeur Général | - |
| Flagship Labs 89, Inc. | Directeur Général | 01/10/2022 |
Anciens postes connus de Lovisa Afzelius
| Sociétés | Poste | Fin |
|---|---|---|
BioChromix Pharma AB
 BioChromix Pharma AB Miscellaneous Commercial ServicesCommercial Services BioChromix Pharma AB was founded as a subsidiary to BioChromix AB. The Company is a pharmaceutical company active in research and development of novel treatments for neurodegenerative disorders based on its proprietary technology for therapeutics. Current research and development is focused on the indication area of Alzheimer's disease but the prion diseases, Parkinson's disease and other neurodegenerative disorders might also be included in the future. BioChromix Pharma is performing pre-clinical development but is looking to reach the clinical phase within the coming years. Alzheimer's disease is the most common neurodegenerative disease, affecting around 25 million people and the costs associated with AD are tremendous. At the moment, there are no efficient treatments for AD but there are clinical trials are ongoing and some are focused at reducing the levels of the neurotoxic Aß peptide. The portfolio of the company includes a number of newly discovered lead compounds that are under investigation. | President | - |
Formation de Lovisa Afzelius
| University of Uppsala | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
BioChromix Pharma AB
BioChromix Pharma AB Miscellaneous Commercial ServicesCommercial Services BioChromix Pharma AB was founded as a subsidiary to BioChromix AB. The Company is a pharmaceutical company active in research and development of novel treatments for neurodegenerative disorders based on its proprietary technology for therapeutics. Current research and development is focused on the indication area of Alzheimer's disease but the prion diseases, Parkinson's disease and other neurodegenerative disorders might also be included in the future. BioChromix Pharma is performing pre-clinical development but is looking to reach the clinical phase within the coming years. Alzheimer's disease is the most common neurodegenerative disease, affecting around 25 million people and the costs associated with AD are tremendous. At the moment, there are no efficient treatments for AD but there are clinical trials are ongoing and some are focused at reducing the levels of the neurotoxic Aß peptide. The portfolio of the company includes a number of newly discovered lead compounds that are under investigation. | Commercial Services |
Elsa Science AB
Elsa Science AB Information Technology ServicesTechnology Services Elsa Science AB provides mobile applications that helps in learning medication and living habits that affect arthritis rheumatism. The firm specializes in healthcare, life science, chronic diseases, research, health and prevention. The company was founded by Sofia Svanteson, Sebastian Evans, Pelle Almquist, Lars Alfredsson and Lovisa Afzelius and is headquartered in Stockholm, Sweden. | Technology Services |
Alltrna
Alltrna BiotechnologyHealth Technology Alltrna is a biotech company that uses AI/ML tools to learn the language of tRNA and develop programmable molecules with therapeutic potential. Alltrna was founded in 2018 by Flagship Pioneering and is based in Cambridge, MA. The company aims to correct diseases by advancing a single tRNA medicine to treat a wide range of diseases with the same underlying genetic mutation. The company's CEOs are Michelle C. Werner and Lovisa Afzelius. | Health Technology |
| Flagship Labs 89, Inc. | Health Technology |
